Combining the CDK4/6 inhibitor palbociclib and the MEK inhibitor trametinib not only reduced growth of patient-derived xenograft models but also enhanced response to PD-1 inhibition in a transplantable tumor model derived from the KPC model (Knudsen et al., 2021). This evidence concerns the gene CDK4 and neoplasm.